Beam Therapeutics Inc. (BEAM)

Market Cap	1.65B
Revenue (ttm)	63.52M
Net Income (ttm)	-376.74M
Shares Out	97.26M
EPS (ttm)	-4.58
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,136,640
Open	16.55
Previous Close	16.62
Day's Range	16.55 - 17.15
52-Week Range	13.53 - 35.25
Beta	2.02
Analysts	Strong Buy
Price Target	50.50 (+210.77%)
Earnings Date	May 6, 2025

About BEAM

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for development in sic...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 6, 2020
• Employees: 483
• Stock Exchange: NASDAQ
• Ticker Symbol: BEAM
• Website: https://beamtx.com

Financial Performance

In 2024, Beam Therapeutics's revenue was $63.52 million, a decrease of -83.18% compared to the previous year's $377.71 million. Losses were -$376.74 million, 184.3% more than in 2023.

Analyst Forecast

According to 11 analysts, the average rating for BEAM stock is "Strong Buy." The 12-month stock price forecast is $50.5, which is an increase of 210.77% from the latest price.

Price Target

$50.5

(210.77% upside)

Analyst Consensus: Strong Buy